VANCOUVER, Aug. 17, 2015 /CNW/ - CRH Medical Corporation (TSX: CRH) (OTCQX: CRMMF) ("CRH"), a North American medical company that provides physicians with innovative products and services for the treatment of gastrointestinal diseases, has filed a Registration Statement on Form 40-F (the "Registration Statement") with the United States Securities and Exchange Commission. CRH also announced that it has submitted an original listing application to list its common shares for trading on the NYSE MKT, LLC. The Registration Statement has not yet become effective.
Following acceptance of the application and effectiveness of the Registration Statement, it is expected that CRH will have the opportunity to begin trading on the NYSE MKT, LLC.
"As the vast majority of our revenue is generated from our US operations, a listing on the NYSE MKT is a logical progression," said Edward Wright, Chief Executive Officer of CRH Medical. "We continue to expand our anesthesia services division, and this listing is an important step in our growth strategy as it increases our direct access to the North American investment community."
CRH is a North American company that provides physicians with innovative products and services for the treatment of gastrointestinal diseases. CRH's product distribution strategy focuses on physician education, patient outcomes, and patient awareness. CRH's first product, the CRH O'Regan System, is a single use, disposable, hemorrhoid banding technology that is safe and highly effective in treating hemorrhoid grades I – IV. CRH distributes the CRH O'Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians, allowing CRH to create meaningful relationships with the physicians it serves. CRH also operates a full service gastroenterology anesthesia services business, which provides anesthesia services to patients undergoing endoscopies and colonoscopies. Performing these procedures under anesthesia provides a greater degree of comfort to the patient and allows the gastroenterologist to perform more procedures than in the absence of anesthesia. CRH expects to leverage its relationships and the capabilities it has attained through acquisitions in order to consolidate the highly fragmented gastroenterology anesthesia provider business. CRH's goal is to establish itself as the premier provider of innovative products and essential services to gastroenterologists throughout the United States. For more information visit our website at www.crhmedcorp.com
Cautionary Note Regarding Forward-Looking Statements:
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such forward-looking statements include approval by the NYSE MKT of CRH's original listing application and the effectiveness of the Registration Statement. Such forward-looking statements are subject to various risks and uncertainties, including risks related to regulatory reviews and the risk factors identified in CRH's filings with the Canadian securities regulators and in the Registration Statement. Although CRH believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. CRH does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.
SOURCE CRH Medical Corporation
For further information: David Matousek, Director of Investor Relations, CRH Medical Corporation, 604.633.1440 x1030, email@example.com - Or - Edward Wright, Chief Executive Officer, CRH Medical Corporation, 604.633.1440 x1008, firstname.lastname@example.org